Vincent-Philippe Lavallée is a clinician scientist who obtained his medical degree at Université de Montréal where he subsequently completed a training in internal medicine and hematology. He then pursued a PhD training in molecular biology and systems biology at the same institution where his work focused on the transcriptomic analysis of different subgroups of acute myeloid leukemias aiming at the identification of new biological determinants, prognosis markers and potential therapeutic targets. He next completed a training in computational biology Memorial Sloan Kettering Cancer to study intra-tumor heterogeneity in acute leukemias using single-cell technologies. Dr. Lavallée joined the hemato-oncology group at CHU Sainte-Justine in 2020 and his clinical interests are acute leukemias and genetic predispositions to these diseases. He is working in the clinical oncology molecular diagnostics laboratory aiming to implement novel sequencing technologies in the clinic for improved molecular diagnosis in pediatric oncology. His research team is determined to map cellular genetic and transcriptomic heterogeneity in leukemias and identify how heterogeneity affects response to therapies. He is also investigating the determinants of clonal evolution that could lead to leukemia and myelodysplastic syndromes in children with germline predisposing mutations.